To validate serine/threonine kinase predictions, we profiled the response of the breast cancer cell BT-474 to five different clinically relevant AKT inhibitors (Fig. 2d, Supplementary Note 3), based on data obtained from Wiechmann et al.35. Here, MARK2 is linked to breast cancer.